Abbott Laboratories (ABT) operating KPIs
ABTNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 28, 2026Score 14/3036% above fair value
$106.20+1.63 (+1.56%)
Close on Oct 30, 2026Market cap $183.77BP/E 34.1Yield 2.26%
Abbott Laboratories consolidated Net Sales ($M) ($M)
Postgres DB financial_values + Form 10-K/10-Q XBRL
Latest, FY2025
44,328
Period ended Dec 31, 2025
Change on a year earlier
+5.7%
41,950 in FY2024
History
19 years
Since FY2007
Sources
15
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Consolidated Net Sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 44,328 | +5.7% | Form 10-K (filed 2026-02-20) ↗ |
| FY2024 | Dec 31, 2024 | 41,950 | +4.6% | Form 10-K (filed 2025-02-21) ↗ |
| FY2023 | Dec 31, 2023 | 40,109 | -8.1% | Form 10-K (filed 2024-02-16) ↗ |
| FY2022 | Dec 31, 2022 | 43,653 | +1.3% | Form 10-K (filed 2023-02-17) ↗ |
| FY2021 | Dec 31, 2021 | 43,075 | +24.5% | Form 10-K (filed 2022-02-18) ↗ |
| FY2020 | Dec 31, 2020 | 34,608 | +8.5% | Form 10-K (filed 2021-02-19) ↗ |
| FY2019 | Dec 31, 2019 | 31,904 | +4.3% | Form 10-K (filed 2020-02-21) ↗ |
| FY2018 | Dec 31, 2018 | 30,578 | +11.6% | Form 10-K (filed 2019-02-22) ↗ |
| FY2017 | Dec 31, 2017 | 27,390 | +31.3% | Form 10-K (filed 2018-02-16) ↗ |
| FY2016 | Dec 31, 2016 | 20,853 | +2.2% | Form 10-K (filed 2017-02-17) ↗ |
| FY2015 | Dec 31, 2015 | 20,405 | +0.8% | Form 10-K (filed 2016-02-19) ↗ |
| FY2014 | Dec 31, 2014 | 20,247 | +3.0% | Form 10-K (filed 2015-02-27) ↗ |
| FY2013 | Dec 31, 2013 | 19,657 | +3.2% | Form 10-K (filed 2015-02-27) ↗ |
| FY2012 | Dec 31, 2012 | 19,050 | -11.0% | Form 10-K (filed 2015-02-27) ↗ |
| FY2011 | Dec 31, 2011 | 21,407 | -39.1% | Form 10-K (filed 2014-02-21) ↗ |
| FY2010 | Dec 31, 2010 | 35,167 | +14.3% | Form 10-K (filed 2011-02-18) ↗ |
| FY2009 | Dec 31, 2009 | 30,765 | +4.2% | Form 10-K (filed 2010-02-19) ↗ |
| FY2008 | Dec 31, 2008 | 29,528 | +13.9% | Form 10-K (filed 2010-02-19) ↗ |
| FY2007 | Dec 31, 2007 | 25,914 | – | Form 10-K (filed 2010-02-19) ↗ |
Breakdown
What makes up consolidated net sales ($m)
- Cost of Products Sold ($M)19,319 · FY2025
- GAAP Gross Margin ($M)23,327 · FY2025
- Research & Development Expense ($M)2,942 · FY2025
- Selling, General & Administrative Expense ($M)12,332 · FY2025
- Operating Earnings ($M)8,053 · FY2025
- Interest Expense ($M)493 · FY2025
- Earnings Before Taxes ($M)8,466 · FY2025
- Taxes on Earnings ($M)1,942 · FY2025
- Net Earnings ($M)6,524 · FY2025
- Diluted Earnings Per Common Share ($/share)3.72 · FY2025
- Weighted-Average Diluted Shares Outstanding (Millions)1,748 · FY2025
Cite this data
StockData. (2026). Abbott Laboratories Consolidated Net Sales ($M) ($M), annual FY2007–FY2025 [Data set]. Compiled from Abbott Laboratories SEC filings and investor materials. https://stockdatahq.com/stocks/abt/kpis/db-is-rev
See every metric in the Abbott Laboratories KPI table. Data updated Oct 29, 2026.